Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
002793 Luoxin Pharmaceuticals Group Stock
- 4.25
- +0.05+1.19%
Market Closed Dec 20 15:00 CST
4.62BMarket Cap-6.63P/E (TTM)
4.33High4.16Low142.88KlotVolume4.21Open4.20Pre Close60.87MTurnover1.32%Turnover RatioLossP/E (Static)1.09BShares5.8052wk High2.20P/B4.62BFloat Cap3.2252wk Low4.62Limit Up1.09BShs Float27.94Historical High3.78Limit Down4.05%Amplitude3.22Historical Low--Dividend TTM4.26Avg Price63.01KlotAsk--Div YieldTTM100Lot Size78.51KlotBid
Luoxin Pharmaceuticals Group Stock News
Luoxin Pharmaceuticals Group Stock (002793.SZ): The employee stock ownership plan for 2024 has been completed through non-trading transfer.
On December 2, 2023, Gelonghui reported that luoxin pharmaceuticals group stock (002793.SZ) announced that on December 2, 2024, the company received the "Securities Transfer Registration Confirmation" issued by the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. The company repurchased securities account held 18,219,503 shares of its stocks, which were transferred on November 29, 2024, to the "Luoxin Pharmaceutical Group Co., Ltd. - 2024 Employee Stock Ownership Plan" specialized securities account through a non-trading transfer. The number of transferred shares accounted for 1.68% of the total share capital of the company, with a transfer price of 2.03 yuan/share.
Express News | More than 10 listed companies disclosed agreement transfer plan announcements this week. The actual controller of chahua modern housewares intends to transfer 15.06% of the shares by agreement.
Express News | Luoxin pharmaceuticals group stock: Rebeprazole sodium enteric-coated tablets have obtained the pharmaceutical registration certificate.
Luoxin Pharmaceuticals Group Stock (002793.SZ) shareholders De Yi Chengdu, De Yi Hengjia, and De Yi Xinhua have terminated the matter of transferring shares to Yan Jinxia.
Luoxin pharmaceuticals group stock (002793.SZ) announcement, the company's shareholder De Yi Chengdu, De Yi Hengjia, De Yi Xinhua, and Yan Jinxia...
Express News | luoxin pharmaceuticals group stock: terminate the agreement to transfer 0.112 billion shares.
luoxin pharmaceuticals group stock (002793.SZ): The holding subsidiary plans to sell 100% equity of its wholly-owned subsidiary Lekang Pharmaceutical.
Grain Alliance News on November 18: Luoxin Pharmaceuticals Group Stock (002793.SZ) announced that, in order to revitalize existing assets and optimize the company's resource allocation, the company's controlling subsidiary Shandong Luoxin plans to sell 100% equity of its wholly-owned subsidiary Lokang Pharmaceutical through the Linyi Equity Trading Center in an open listing manner. The listing price is determined to be 190 million yuan based on Lokang Pharmaceutical's latest net assets amount and considering the net asset increase after the debt-for-equity swaps in November 2024 (the final transaction price is subject to the open listing results). After this transaction is completed, Shandong Luoxin, the company's controlling subsidiary, will no longer hold equity in Lokang Pharmaceuticals, and Lokang Pharmaceuticals will not
Luoxin Pharmaceutical: Report for the third quarter of 2024
luoxin pharmaceuticals group stock (002793.SZ) achieved revenue of 1.881 billion yuan in the first three quarters, a year-on-year increase of 2.98%.
Gelonghui October 29th | luoxin pharmaceuticals group stock (002793.SZ) released the third quarter report of 2024, the company achieved revenue of 1.881 billion yuan in the first three quarters, a year-on-year increase of 2.98%; with a net loss of 0.265 billion yuan. Among them, the third quarter achieved revenue of 0.622 billion yuan, a year-on-year increase of 8.87%; with a net loss of 0.177 billion yuan.
Luoxin Pharmaceuticals Group Stock (002793.SZ): Tegora tablets obtain new indications for drug registration certificate.
luoxin pharmaceuticals group stock (002793.SZ) announced recently that its subsidiary Shandong luoxin pharmaceuticals group stock has...
Express News | Luoxin Pharmaceuticals Group Stock: Tegretol tablets new indications obtained pharmaceutical registration certificate.
Luoxin Pharmaceuticals Group Stock (002793.SZ): Yan Jinxia will hold 0.102 billion shares and become a shareholder with more than 5% ownership.
Luoxin Pharmaceuticals Group Stock (002793.SZ) announced that the company, together with shareholders holding more than 5% of the shares, Chengdu Dexin Huahua Private Equity Investment...
Express News | Luoxin Pharmaceuticals Group Stock: Shareholders intend to transfer 0.102 billion shares of the company by agreement.
Luoxin Pharmaceuticals Group Stock (002793.SZ): The company has not yet been involved in ai-related businesses.
gelunhui September 30th | luoxin pharmaceuticals group stock (002793.SZ) stated on the investor interaction platform that the company has not yet been involved in such ai-related businesses.
luoxin pharmaceuticals group stock (002793.SZ): plans to launch employee stock ownership plan in 2024.
On September 27th, Greenland Securities reported that Luoxin Pharmaceutical Group Stock (002793.SZ) announced the employee stock ownership plan for 2024. The stocks for this employee stock ownership plan are sourced from the company's special repurchase account for repurchasing Luoxin Pharmaceutical Group Stock A ordinary shares. The target number of stocks intended to be held in this employee stock ownership plan is not more than 26.027861 million shares, approximately 2.39% of the company's total share capital of 1087.588486 million shares on the day the draft of this employee stock ownership plan was announced. After the implementation of this employee stock ownership plan, the total number of stocks held by all effective employee stock ownership plans in the company does not exceed 10% of the company's total share capital; individual employees will not hold more than
Head accounting firms have also been heavily penalized, with penalties directly related to ten violations. Currently, there are 53 IPO projects under review.
luoxin pharmaceuticals group stock's financial report audit has ten major professional issues, Tianjian Accounting Firm has been warned; Tianjian Accounting Firm is currently conducting audits for a total of 86 projects, including 53 IPO projects under review; 34 accounting firms have been fined this year, and the key is to strengthen the responsibility of the 'gatekeepers'.
Luoxin Pharmaceutical: 2024 Semi-Annual Report
Luoxin Pharmaceutical: 2024 Semi-Annual Report Summary
Luoxin Pharmaceutical Group Stock (002793.SZ) released its performance for the first half of the year, with a net loss of 88.7099 million yuan.
Luoxin Pharmaceuticals Group (002793.SZ) released its semi-annual report for 2024. During the reporting period, the company achieved revenue...
Luoxin Pharmaceuticals Group Stock (002793.SZ): Net loss of 88.7099 million yuan in the first half of the year, narrower loss compared to the same period last year.
Luoxin Pharmaceuticals Group Stock (002793.SZ) released its semi-annual report for 2024, with revenue of 1.259 billion yuan, a year-on-year increase of 0.30%; net income attributable to shareholders of the listed company was -88.7099 million yuan, narrowing the loss; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.108 billion yuan; basic earnings per share was -0.08 yuan.
Express News | Luoxin Pharmaceuticals Group Stock received a regulatory letter from the Shenzhen Stock Exchange, indicating the existence of violations such as inaccurate disclosure of revenue.
